false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Glomeru ...
Evaluation and Management of Patients with ANCA-Po ...
Evaluation and Management of Patients with ANCA-Positive Serologies
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Coyle Jane presented a case-based review of ANCA-associated vasculitis, emphasizing individualized treatment for organ-threatening disease. For severe kidney or pulmonary involvement, she favors rituximab plus a limited course of cyclophosphamide; rituximab alone is also effective, particularly for PR3-positive or relapsing disease.<br /><br />Plasma exchange is not recommended routinely, given mixed trial results and infection risks. She would consider it for selected patients with severe, potentially reversible acute kidney injury, severe hypoxemic pulmonary hemorrhage, or anti-GBM overlap. Kidney biopsy can help assess active injury versus chronic scarring and guide prognosis.<br /><br />The talk supported reduced-dose, rapidly tapered steroids to limit infections and other toxicity; at her center, patients often stop steroids within 12–16 weeks. Avacopan use was described as controversial following retraction of the ADVOCATE trial, with close liver monitoring advised if it is used.<br /><br />For maintenance, she generally prefers rituximab, often at 500-mg doses, over azathioprine, while using CD19 B-cell counts and clinical findings to guide redosing. Treatment duration remains uncertain: she typically aims for one to two years, then considers stopping with close follow-up and on-demand retreatment. PR3 positivity and ENT or lung involvement raise relapse risk; persistent ANCA alone does not necessarily require continued therapy.
Asset Caption
Koyal Jain, MD, MEd, MPH, FASN
Meta Tag
Speaker
Koyal Jain
Keywords
ANCA-associated vasculitis
rituximab
cyclophosphamide
plasma exchange
kidney biopsy
reduced-dose steroids
maintenance therapy
×
Please select your language
1
English